

National Cancer Institute (NCI)
Experimental Therapeutics Clinical Trials Network (ETCTN) Guidance

ETCTN Site Selection and Funding Information Sheet

The ETCTN consists of academic centers with expertise in oncology drug development. One intramural component, the NCI Developmental Therapeutics Clinic, and eleven extramural Lead Academic Organizations (LAOs), one of which being the Dana-Farber/Harvard Cancer Center LAO, make up the ETCTN. A list of the current LAOs and the institutions that fall under each one can be found on the [CTEP website](#).

CTEP provides UM1 grant funding to LAOs to conduct phase I and phase II clinical trials. The DF/HCC UM1 grant is used to cover the costs associated with participants enrolled at DF/HCC only. This includes data collection/management and biospecimen collection; however, funding for research laboratory tests may require support from other resources. When a DF/HCC investigator serves as the Protocol Chair for an ETCTN study, the participating LAOs use their own UM1 grant funds to cover the costs of having their institution participate on the study. No UM1 grant funds are transferred from DF/HCC to participating organizations and other ETCTN LAOs do not provide DF/HCC funding when a study they are leading is opened at DF/HCC.

Other programs, such as the [NCI Early Drug Development Opportunity Program](#) (EDDOP), allow non-ETCTN institutions to lead and/or participate in select ETCTN trials. If a DF/HCC investigator is serving as the Protocol Chair for an ETCTN study and he or she wishes to add non-ETCTN participating site(s) either through EDDOP or another mechanism, he or she must discuss the plan with [ETCTN Program Leadership](#) prior to implementation.

Links

CTEP ETCTN Website: <https://ctep.cancer.gov/initiativesPrograms/etctn.htm>

CTEP EDDOP Website: <https://ctep.cancer.gov/initiativesPrograms/eddop.htm>